While this is hypothesis generating, given the feasibility of assessing CTC enumeration and biomarker analyses that are possible due to the intact membrane structure of circulating tumor cells as opposed to ctDNA, CTCs may have more value for assessing cell-surface protein-based biomarkers such as HER2, PD-L1, and beyond. The gene discussed is ERBB2; the disease is neoplasm.